| Active ingredient (INN) | Methotrexate |
|---|---|
| Brand names | Rasuvo, Otrexup, Methofar, Methotrexate Lederle |
| ATC level 5 | L01BA01 |
| ATC level 4 | L01BA |
| Drug class | Antimetabolite / DMARD |
| Therapeutic category | Oncology/Immunology |
| Strength | 2.5mg · 7.5mg · 10mg · 15mg · 20mg · 25mg · 50mg/2ml injection |
| Dosage form | tablet · solution for injection |
| Route of administration | oral · subcutaneous · intramuscular · intrathecal |
| WHO Essential Medicine | Yes (2023) |
| Controlled substance | No |
| Marketing-authorisation holders | Cipla Australia Pty Ltd, Boucher & Muir Pty Ltd, Pfizer Australia Pty Ltd, Accord Healthcare Pty Ltd +3 more |
| Registrations on file | 30 |
| Patient information leaflet (PIL) | Not on file |
| Summary of product characteristics (SPC) | Not on file |
| Product | Strength | Form | Market | MA holder | Status |
|---|---|---|---|---|---|
| CHEXATE methotrexate | 10 mg | — | 🇦🇺 AU | — | Active |
| Imutrex | 10 mg | — | 🇦🇺 AU | Cipla Australia Pty Ltd | Active |
| Methotrexate Cipla | 2.5 mg | — | 🇦🇺 AU | Cipla Australia Pty Ltd | Active |
| Arx-Methotrexate | 10 mg | — | 🇦🇺 AU | Cipla Australia Pty Ltd | Active |
| Imutrex | 2.5 mg | — | 🇦🇺 AU | Cipla Australia Pty Ltd | Active |
| Methotrexate Cipla | 10 mg | — | 🇦🇺 AU | Cipla Australia Pty Ltd | Active |
| Arx-Methotrexate | 2.5 mg | — | 🇦🇺 AU | Cipla Australia Pty Ltd | Active |
| CHEXATE methotrexate | 2.5 mg | — | 🇦🇺 AU | — | Active |
| Arx | 10 mg | — | 🇦🇺 AU | Boucher & Muir Pty Ltd | Active |
| Arx | 15 mg | — | 🇦🇺 AU | Boucher & Muir Pty Ltd | Active |
| Advz | 7.5 mg | — | 🇦🇺 AU | Boucher & Muir Pty Ltd | Active |
| Advz | 10 mg | — | 🇦🇺 AU | Boucher & Muir Pty Ltd | Active |
| Advz | 15 mg | — | 🇦🇺 AU | Boucher & Muir Pty Ltd | Active |
| Advz | 20 mg | — | 🇦🇺 AU | Boucher & Muir Pty Ltd | Active |
| Advz | 25 mg | — | 🇦🇺 AU | Boucher & Muir Pty Ltd | Active |